What is clear cell sarcoma of soft tissue?
Clear cell sarcoma is a rare cancer of the soft tissues. It usually grows from a tendon or the tough sheets of tissue (aponeuroses) around it, most often in the foot, ankle or around the knee.
It mainly affects young adults, typically between 20 and 40. The first sign is often a small, slow-growing lump that may be present for months or years before it is checked.
Under the microscope, the cancer cells often look pale or “clear” and make the same proteins as pigment cells (melanocytes). For this reason it was once called “malignant melanoma of soft parts”.
It is not a skin melanoma, however. Almost every clear cell sarcoma carries a specific gene fusion, EWSR1::ATF1, which skin melanoma does not have.
Unlike most sarcomas, clear cell sarcoma often spreads to lymph nodes, as well as to the lungs. The main treatment is wide surgery, sometimes with radiotherapy. Drug treatments for advanced disease work less well than for many other cancers, so clinical trials are important.
1. Key facts at a glance
| Feature | Details |
|---|---|
| Type of cancer | Soft-tissue sarcoma with melanocytic features |
| How common | Under 1% of soft-tissue sarcomas |
| Typical age | Mostly 20-40; uncommon in children and older adults |
| Sex | Men and women are affected about equally |
| Main sites | Foot and ankle, knee, thigh, hand and wrist; usually deep, attached to tendons |
| Key gene change | EWSR1::ATF1 fusion in over 90%; EWSR1::CREB1 in a minority |
| Spread | Lymph nodes and lungs; also bone and liver |
| Main treatments | Wide surgery, radiotherapy, lymph node surgery if needed; drugs and trials for advanced disease |
| Outlook | About 50-65% alive at 5 years overall; much better for small tumours without spread |
2. Clear cell sarcoma and similar tumours
Several different tumours share the name “clear cell” or look similar. They are separate diseases.
| Tumour | How it differs |
|---|---|
| Clear cell sarcoma of soft tissue | Deep tumour of tendons in young adults; EWSR1::ATF1 fusion |
| Skin (cutaneous) melanoma | Starts in the skin, often from a mole; has BRAF, NRAS or other mutations, not EWSR1 fusions |
| Malignant gastrointestinal neuroectodermal tumour | Previously called clear cell sarcoma-like tumour of the gut; grows in the bowel wall; often EWSR1::CREB1 |
| Clear cell sarcoma of the kidney | A childhood kidney cancer with BCOR or YWHAE changes; not related |
| Clear cell renal cell carcinoma | The commonest adult kidney cancer; not a sarcoma |
3. Causes and risk factors
The cause of clear cell sarcoma is not known. It is not caused by sun exposure, injury or lifestyle.
| Factor | Notes |
|---|---|
| EWSR1::ATF1 fusion | A swap between chromosomes 12 and 22, t(12;22), inside the tumour cells. The fusion protein switches on genes normally used by pigment cells, such as MITF |
| EWSR1::CREB1 fusion | A related fusion, t(2;22), found in a small group of cases |
| Inherited risk | No inherited syndrome is linked to it; it is not passed on in families |
| Previous injury | People often remember a knock to the area, but this is thought to draw attention to the lump rather than cause it |
4. How does it look?
4.1 On the body
| Feature | What it looks or feels like |
|---|---|
| Lump | A firm, rubbery lump deep under the skin, often 2-5 cm across, near the heel, ankle, knee or wrist |
| Growth | Usually slow; may stay small for a long time |
| Skin | Normal over the lump; it does not usually look dark like a melanoma |
| Attachment | Often feels fixed to a tendon and may move a little when the tendon moves |
| Lymph nodes | Swollen glands behind the knee or in the groin or armpit if it has spread |
4.2 On scans
| Test | Typical findings |
|---|---|
| Ultrasound | A solid, well-defined mass next to a tendon, often with blood flow |
| MRI | The main test; shows a lobulated mass, sometimes slightly bright on T1 images because of melanin, and enhancing after contrast |
| CT chest | Looks for spread to the lungs |
| PET-CT | Helps check the lymph nodes and other sites of spread |
4.3 Under the microscope
| Feature | What the pathologist sees |
|---|---|
| Pattern | Nests and bundles of cells separated by thin fibrous bands |
| Cells | Round or spindle-shaped cells with pale or clear cytoplasm and prominent nucleoli |
| Giant cells | Wreath-like giant cells with several nuclei are common |
| Pigment | Melanin pigment is seen in some tumours |
| Stains | Positive for S100, SOX10, HMB-45 and Melan-A, like melanoma |
| Genetic test | FISH, RT-PCR or sequencing shows EWSR1 rearrangement with ATF1 or CREB1; this separates it from melanoma |
5. Symptoms
Many people have no symptoms other than a lump. Because it can grow slowly, it is often mistaken for a ganglion, a cyst or a sports injury.
5.1 Common symptoms
| Symptom | Notes |
|---|---|
| Painless lump | The most common first sign, often in the foot, ankle or around the knee |
| Pain or tenderness | Present in some people, especially with walking or pressure from shoes |
| Stiffness | Reduced movement of a nearby joint or tendon |
| Numbness or tingling | If the tumour presses on a nerve |
| A lump that comes back | After it was removed as a “benign” lump without a full diagnosis |
5.2 Symptoms of spread
| Area | Possible symptoms |
|---|---|
| Lymph nodes | Firm, painless swelling in the groin, behind the knee or in the armpit |
| Lungs | Cough or breathlessness, often only late |
| Bone | Bone pain |
| Liver | Pain under the right ribs, loss of appetite |
| General | Tiredness and weight loss in advanced disease |
5.3 When to see a doctor
Ask for a medical review if a lump:
- Is deep or attached to a tendon
- Is larger than about 5 cm, or keeps getting bigger
- Is painful or limits movement
- Comes back after removal
These features do not mean cancer, but they are reasons for an MRI scan and a referral to a sarcoma centre before any operation.
6. Diagnosis
The diagnosis should be made at a specialist sarcoma centre, because clear cell sarcoma is easy to confuse with melanoma and with benign lumps.
| Test | Why it is done |
|---|---|
| MRI of the lump | Shows size, depth and the relation to tendons, nerves and vessels |
| Core needle biopsy | Provides tissue for microscopy, stains and genetic tests; planned so the track can be removed later |
| Fusion testing | Confirms EWSR1::ATF1 or EWSR1::CREB1 and separates the tumour from melanoma |
| Skin examination | Rules out a skin melanoma that could have spread |
| CT chest | Looks for lung spread |
| Lymph node assessment | Ultrasound or PET-CT; sentinel lymph node biopsy is used in some centres |
| Blood tests | General health before treatment |
Staging
Clear cell sarcoma is staged with the AJCC/UICC TNM system for soft-tissue sarcoma. This looks at tumour size (T), lymph node spread (N) and distant spread (M), along with tumour grade. Clear cell sarcoma is treated as a high-grade sarcoma.
7. Treatment
7.1 Localised disease
| Treatment | What it involves | Notes |
|---|---|---|
| Wide surgical excision | Removal of the tumour with a margin of healthy tissue | The main and most important treatment; may need tendon repair or reconstruction |
| Amputation | Removal of part of the foot, hand or limb | Rarely needed today; used when wide surgery would leave a useless limb |
| Radiotherapy | Given before or after surgery | Lowers the chance of the tumour coming back locally, especially for large tumours or close margins |
| Lymph node surgery | Removal of affected lymph nodes | Done when nodes contain cancer; sentinel node biopsy may be offered |
| Chemotherapy | Doxorubicin-based drugs | Not routinely given for localised disease, because benefit is uncertain |
7.2 Advanced or recurrent disease
| Option | Notes |
|---|---|
| Surgery for isolated spread | Removal of a single lung spot or a lymph node recurrence can give long control in selected people |
| Chemotherapy | Doxorubicin, ifosfamide or other sarcoma drugs; responses are uncommon and usually short |
| Targeted drugs | Drugs such as crizotinib or sunitinib (acting on MET and other pathways) have been tried, with small benefit in some patients |
| Immunotherapy | Immune checkpoint drugs such as pembrolizumab, nivolumab or ipilimumab have produced occasional lasting responses |
| Radiotherapy | Relieves pain or controls a single troublesome site |
| Clinical trials | Strongly recommended, because no standard drug works well |
8. Side effects of treatment
| Treatment | Possible effects | What helps |
|---|---|---|
| Surgery on foot or hand | Pain, stiffness, wound problems, change in walking or grip | Physiotherapy, orthotics, hand therapy |
| Radiotherapy | Skin redness, wound healing problems (especially before surgery), later stiffness and swelling | Skin care, stretching, lymphoedema advice |
| Lymph node removal | Swelling of the limb (lymphoedema) | Compression garments, specialist therapy |
| Chemotherapy | Tiredness, hair loss, infections, nausea | Supportive medicines, blood tests |
| Immunotherapy | Inflammation of the skin, gut, liver, lungs or hormone glands | Early reporting, steroids if needed |
9. Outlook
Clear cell sarcoma can come back many years after treatment, so follow-up is long.
| Situation | What to expect |
|---|---|
| Small tumour (under 5 cm), fully removed, no spread | Good chance of long-term cure |
| Large tumour or close margins | Higher risk of recurrence in the same area and of later spread |
| Lymph node spread | Worse outlook, but some people are cured with surgery and radiotherapy |
| Distant spread | Usually not curable; survival is often counted in months to a few years, though some live longer |
| Overall | Roughly 50-65% of people are alive 5 years after diagnosis |
The most important factors are tumour size, depth, necrosis and whether it has spread at diagnosis.
10. Follow-up and living with clear cell sarcoma
| Time after treatment | Typical follow-up |
|---|---|
| Years 1-3 | Examination, MRI of the treated site and chest imaging every 3-4 months |
| Years 4-5 | Every 6 months |
| After 5 years | Yearly, often for 10 years, because late recurrence happens |
Report any new lump, swelling of lymph nodes or a cough that does not settle.
After foot or hand surgery, rehabilitation helps people return to walking, sport and work. Patient groups for sarcoma offer support and information for this rare cancer.
11. Frequently asked questions
| Question | Answer |
|---|---|
| Is this a type of melanoma? | No. It looks like melanoma under the microscope, but it is a sarcoma with its own gene fusion and is treated as a sarcoma |
| Did the sun cause it? | No. It grows deep in the body and is not linked to sun exposure |
| Why check my lymph nodes? | Clear cell sarcoma spreads to nodes much more often than other sarcomas |
| Will I lose my foot? | Most people keep their limb. Amputation is only considered when the tumour cannot be removed otherwise |
| Can I play sport again? | Many people can, after healing and rehabilitation, depending on the surgery |
12. Questions to ask your care team
- Has my tumour been tested for the EWSR1 fusion, and has a sarcoma pathologist reviewed it?
- How big is the tumour, how deep is it, and has it reached any lymph nodes?
- Will I need radiotherapy, and would it be given before or after surgery?
- What will surgery mean for walking, grip, work and sport?
- Should my lymph nodes be checked with a sentinel node biopsy?
- How often will I have scans, and for how many years?
- Are there clinical trials I could join now or if the cancer returns?
Writing questions down before each appointment, and bringing someone with you, makes it easier to remember the answers. Your specialist nurse is usually the best first contact between visits.
Resources
- WHO Classification of Tumours Editorial Board (2020) Soft Tissue and Bone Tumours. 5th edn. Lyon: International Agency for Research on Cancer.
- Enzinger, F.M. (1965) ‘Clear-cell sarcoma of tendons and aponeuroses. An analysis of 21 cases’, Cancer, 18, pp. 1163-1174.
- Chung, E.B. and Enzinger, F.M. (1983) ‘Malignant melanoma of soft parts. A reassessment of clear cell sarcoma’, American Journal of Surgical Pathology, 7(5), pp. 405-413.
- Hisaoka, M. et al. (2008) ‘Clear cell sarcoma of soft tissue: a clinicopathologic, immunohistochemical, and molecular analysis of 33 cases’, American Journal of Surgical Pathology, 32(3), pp. 452-460.
- Takemori, T. et al. (2024) ‘Clear cell sarcoma in Japan: an analysis of the population-based cancer registry in Japan’, Japanese Journal of Clinical Oncology, 54(12), pp. 1281-1287.
- Smrke, A. et al. (2022) ‘Systemic treatment of advanced clear cell sarcoma: results from a retrospective international series from the World Sarcoma Network’, ESMO Open, 7(3), 100522.
- Gronchi, A. et al. (2021) ‘Soft tissue and visceral sarcomas: ESMO-EURACAN-GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up’, Annals of Oncology, 32(11), pp. 1348-1365.
- National Cancer Institute (2026) Adult Soft Tissue Sarcoma Treatment (PDQ) – Health Professional Version. Available at: https://www.cancer.gov/types/soft-tissue-sarcoma/hp/adult-soft-tissue-treatment-pdq (Accessed: October 2026).
Prepared by the editorial team, October 2026.